Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR (“Research on Adverse Drug events And Reports”) program

Kelsey A. Orrell, Morgan Murphrey, Ryan C. Kelm, Harrison H. Lee, David R. Pease, Anne E. Laumann, Dennis P. West, Beatrice Nardone*

*Corresponding author for this work

Research output: Contribution to journalArticle

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)777-778
Number of pages2
JournalJournal of the American Academy of Dermatology
Volume79
Issue number4
DOIs
StatePublished - Oct 2018

ASJC Scopus subject areas

  • Dermatology

Cite this